Abstract
Pancreatic cancer is a highly lethal disease with one of the highest morbidity/mortality ratio among all major solid cancers. This is partially a result of the frequent failure of diagnostics at its early stages. Scientists and health care employees worldwide try to find new strategies for early diagnostics of pancreatic cancer. Improved imaging capabilities have not brought all expected advances yet and could hardly be applied as a first choice screening method in large populations. Therefore, biomarker research seems to be an attractive option for the screening and diagnostics of pancreatic cancer. Due to the recent technical innovations, proteomics seems to be a very promising method for biomarkers research at the time. Recently published studies in this field reveal an increasing number of potential new pancreatic cancer biomarkers, such as galectins, DJ-1, S100 family proteins, apolipoproteins, transglutaminase 2 and others. Establishment of a sensitive and specific set of biomarkers will lead to a breakthrough in the pancreatic cancer management and survival. The most promising proteins with potential to be used in future for early diagnostics and treatment personalization of pancreatic cancer are reviewed in this manuscript.
Keywords: Apolipoproteins, cancer biomarkers, DJ-1, S100 family proteins, galectins, pancreatic cancer, proteomics, transglutaminase 2.
Current Proteomics
Title:Current Role of Proteomics in Pancreatic Cancer Biomarkers Research
Volume: 13 Issue: 1
Author(s): Audrius Sileikis, Marius Petrulionis, Benediktas Kurlinkus, Marija Ger, Algirdas Kaupinis, Jonas Cicenas, Mindaugas Valius and Kestutis Strupas
Affiliation:
Keywords: Apolipoproteins, cancer biomarkers, DJ-1, S100 family proteins, galectins, pancreatic cancer, proteomics, transglutaminase 2.
Abstract: Pancreatic cancer is a highly lethal disease with one of the highest morbidity/mortality ratio among all major solid cancers. This is partially a result of the frequent failure of diagnostics at its early stages. Scientists and health care employees worldwide try to find new strategies for early diagnostics of pancreatic cancer. Improved imaging capabilities have not brought all expected advances yet and could hardly be applied as a first choice screening method in large populations. Therefore, biomarker research seems to be an attractive option for the screening and diagnostics of pancreatic cancer. Due to the recent technical innovations, proteomics seems to be a very promising method for biomarkers research at the time. Recently published studies in this field reveal an increasing number of potential new pancreatic cancer biomarkers, such as galectins, DJ-1, S100 family proteins, apolipoproteins, transglutaminase 2 and others. Establishment of a sensitive and specific set of biomarkers will lead to a breakthrough in the pancreatic cancer management and survival. The most promising proteins with potential to be used in future for early diagnostics and treatment personalization of pancreatic cancer are reviewed in this manuscript.
Export Options
About this article
Cite this article as:
Sileikis Audrius, Petrulionis Marius, Kurlinkus Benediktas, Ger Marija, Kaupinis Algirdas, Cicenas Jonas, Valius Mindaugas and Strupas Kestutis, Current Role of Proteomics in Pancreatic Cancer Biomarkers Research, Current Proteomics 2016; 13 (1) . https://dx.doi.org/10.2174/1570164613666160413130201
DOI https://dx.doi.org/10.2174/1570164613666160413130201 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Structural Chromosome Abnormalities Associated with Obesity: Report of Four New Subjects and Review of Literature
Current Genomics Editorial Nutritional Therapy in Metabolic Syndrome
Current Vascular Pharmacology Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Phytol a Natural Diterpenoid with Pharmacological Applications on Central Nervous System: A Review
Recent Patents on Biotechnology Molecular Modeling Investigation of Folic Acid Conjugation to MDM2 Inhibitors for Enhanced Cellular Uptake and Target Binding
Current Computer-Aided Drug Design Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Vascular Dysfunction in Aging: Potential Effects of Resveratrol, an Anti- Inflammatory Phytoestrogen
Current Medicinal Chemistry Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Letters in Drug Design & Discovery Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology A New Practice: Study on the Molecular Mechanism of Traditional Chinese Medicine by Computational Pharmacology Methods: Part 2: Pharmacodynamic Modeling and Distribution on Ligand-Target Space of Effective Components
Letters in Drug Design & Discovery Aging as an Evolvability-Increasing Program Which can be Switched Off by Organism to Mobilize Additional Resources for Survival
Current Aging Science Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Highest Mortality During the Last Year Before and the First Year After Start of Dialysis Treatment in Type 2 Diabetic Patients with Nephropathy
Current Diabetes Reviews